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ABSTRACT 
Objective: To verify if the bronchoprovocation test with 
4.5% hypertonic saline solution allows to detect the gradient 
of response in asthmatic children and adolescents, according 
to asthma severity.
Methods: 75 asthmatic patients aged six to 18 years-
old were evaluated in this cross-sectional study. They were 
classified according to asthma severity in: intermittent 
or mild persistent (IM) and moderate or severe persistent 
(MS). They were also classified according to sensitization 
to inhaled allergens in atopics: positive skin prick test to 
Dermatophagoides pteronyssinus, D. farinae and Blomia tropicalis; 
or non- atopic with negative skin prick tests. All patients 
underwent a bronchoprovocation test with 4.5% hypertonic 
saline solution. The result of the bronchoprovocation test 
was considerd positive if at least a reduction of 20% in the 
forced expiratory volume in one second (FEV
1
) was noted. 
Results: 60 individuals were atopic. The bronchoprovo-
cation test was positive more frequently in the MS group 
than in the IM one (93 versus 65%). Less time was needed 
for a 20% fall of FEV
1
 in the MG compared to the IL group 
[90 (30–330) versus 210 (30–690) seconds; p<0.05]. The 
percentage of FEV
1 
fall was higher in the MG group than 
in the IL one [26,4% (14–63) versus 20% (0–60); p<0.05]. 
Conclusions: The 4.5% hypertonic saline solution bron-
choprovocation test is safe and easy to perform. It detects a 
gradient of response in asthmatic children and adolescents 
regarding asthma severity. Higher frequency of positive tests, 
shorter time for FEV
1
 fall, and higher percentage of FEV
1
 
fall were observed in moderate and severe asthmatic patients.
Key-words: asthma; saline solution, hypertonic; 
spirometry.
RESUMO
Objetivo: Verificar se o teste de broncoprovocação, com 
solução salina hipertônica a 4,5%, permite detectar o gra-
diente de resposta em crianças e adolescentes com asma, 
segundo a gravidade da enfermidade.
Métodos: Estudo transversal composto por 75 pacientes 
asmáticos com idades entre seis e 18 anos. Os pacientes foram 
classificados pela gravidade (intermitente associada à persisten-
te leve – IL,  e persistente moderada associada à grave – MG) 
e segundo a presença de sensibilização a aeroalérgenos (testes 
cutâneos de hipersensibilidade imediata a Dermatophagoides 
pteronyssinus, D. farinae e Blomia tropicalis) ou não (atópicos 
versus não atópicos). Todos foram submetidos ao teste de 
broncoprovocação com solução salina hipertônica a 4,5%, 
considerando-se o resultado positivo se havia redução do vo-
lume expiratório forçado no primeiro segundo (VEF
1
) ≥20%.
Resultados: 60 indivíduos eram atópicos. A frequência 
de positividade do teste de broncoprovocação foi maior no 
Grupo MG do que no IL (93 versus 65%). O tempo necessário 
para a queda de 20% do VEF
1
 para o grupo de atópicos foi 
menor no MG quando comparado ao IL: 90 (30–330) versus 
210 (30–690) segundos, com p<0,05. A porcentagem de 
queda do VEF
1
 foi mais acentuada no subgrupo MG do que 
no IL [26,4% (14–63) versus 20% (0–60), p<0,05].
Conclusões: O teste de broncoprovocação com solução sali-
na hipertônica a 4,5% é de fácil realização e seguro, permitindo 
detectar gradiente de resposta em crianças e adolescentes com 
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asma segundo a gravidade da mesma. A maior frequência de 
positividade e a queda mais rápida do VEF
1
 foram observadas 
nos pacientes com asma moderada ou grave.
Palavras-chave: asma; solução salina hipertônica; espi-
rometria.
RESUMEN
Objetivo: Verificar si la prueba de broncoprovocación, 
con solución salina hipertónica a 4,5%, permite detectar 
el gradiente de respuesta en niños y adolescentes con asma, 
según la gravedad de la enfermedad.
Métodos: Estudio transversal, compuesto por 75 pacientes 
asmáticos, con edades entre seis y 18 años. Los pacientes fueron 
clasificados por la gravedad (intermitente asociada a persistente 
liviana - IL - y persistente moderada asociada a grave - MG) y 
según la presencia de sensibilización a aeroalérgenos (pruebas 
cutáneas de hipersensibilidad inmediata a Dermatophagoides 
pteronyssinus, D. farinae y Blomita tropicalis) o no (atópicos 
versus no atópicos). Todos fueron sometidos a la prueba de 
broncoprovocación con solución salina hipertónica a 4,5%, 
considerándose el resultado positivo como la reducción del vo-
lumen espiratorio forzado en el primer segundo (VEF1) ≥20%.
Resultados: Sesenta individuos eran atópicos. La fre-
cuencia de positividad de la prueba de broncoprovocación 
fue mayor en el Grupo MG que en el IL (93 versus 65%). El 
tiempo necesario para la reducción de 20% del VEF1 para 
el grupo de atópicos fue menor en el MG cuando compa-
rado al IL, 90 (30 a 330) versus 210 (30 a 690) segundos, 
con p<0,05. El porcentaje de reducción del VEF1 fue más 
acentuada en el subgrupo MG que en el IL, 26,4 (14 a 63%) 
versus 20% (0 a 60%), p<0,05.
Conclusiones: La prueba de broncoprovocación con solución 
salina hipertónica a 4,5% es de fácil realización y segura, per-
mitiendo detectar el gradiente de respuesta en niños y adoles-
centes con asma, según la gravedad de la enfermedad. La mayor 
frecuencia de positividad y la reducción más rápida del VEF1 
fueron observadas en los pacientes con asma moderada o grave.
Palabras clave: asma; solución salina hipertónica; 
espirometría.
Introduction
In Brazil, asthma is responsible for 350,000 hospi-
talizations annually, and it is the fourth leading cause of 
hospitalization in the Brazilian public Unified Health 
System (SUS), and the third among children and young 
adults. It is defined as a chronic inflammatory disease, char-
acterized by hyperreactivity of the lower airways and airflow 
limitation, with spontaneous reversion or by treatment. 
It is classified regarding severity, according to clinic and 
spirometric parameters, in: intermittent, mild persistent, 
moderate persistent, and severe persistent(1).
The assessment of pulmonary function is the method of 
choice to determine the restriction of airflow and establishing 
the diagnosis of asthma. In symptomatic individuals with 
normal spirometry, the diagnosis of asthma can be confirmed 
by demonstrating the presence of bronchial hyperreactivity 
(BH) through bronchoprovocation tests (BPTs), which re-
flect the sensitivity or the ease of airway response to external 
stimuli or a marked response to β-2 agonist agents(1).
The BPTs considered gold standard are those using phar-
macological agents such as histamine and methacholine(2-4). 
However, the difficulty of access to these agents has motivated 
the search for alternative provocative agents. In 1981, there 
was the first report of the use of hypertonic saline solution 
(HSS)(4). Inhalation on HSS increases water loss via airways 
to the outside world. After such osmolar stimulus, the release 
of mediators from bronchial mucosa cells occurs, causing the 
contraction of the smooth muscle and then bronchospasm(4-6).
BPT with HSS has good sensibility and specificity in the 
assessment of BH in children and adolescents. Although BH 
occurs in normal asymptomatic patients, patients with asth-
ma have it more often(6-10). In asthmatic patients, BPT with 
methacholine, although not universally, require gradient 
in the concentration of drug needed to induce the decrease 
of 20% or more in the forced expiratory volume in the first 
second (FEV
1
) in relation to asthma severity. In most cases, 
more severe cases of asthma need lower doses of methacholine 
to induce the same level of bronchoconstriction(2).
In this context, the objective of this study was to verify 
if a BPT with HSS at 4.5% allows detecting gradient of 
response according to disease severity and the presence 
of atopy in asthmatic children and adolescents. 
Method
This was a cross-sectional study, in which the sample size 
calculation was based on a pilot study with 14 individuals. 
These patients presented: intermittent asthma (three), with 
mean of 11.6 years and reduction of 20% of FEV
1
 in mean 
time of 5 minutes (30 seconds to 9 minutes and 30 seconds); 
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persistent mild asthma (six), with mean of 8.1 years and mean 
time of decrease of 3 minutes and 54 seconds (1 minute and 
30 seconds to 5 minutes and 30 seconds); moderate persis-
tent asthma (three), with mean of 9.6 years and mean time 
of decrease in 2 minutes and 10 seconds (1 minute and 30 
seconds to 3 minutes and 30 seconds); and severe persistent 
asthma (two), both with 11 years and mean time of decrease 
of 5 minutes and 30 seconds. Using as variable the time of 
FEV
1
 decline (in seconds), considering the maximum error 
acceptable of 30 seconds, significance level of 5% and power 
of 80%, it would be necessary to include 75 patients. In this 
pilot study, it was found that children aged 6 or older had 
an adequate cognitive development to participate in the test.
The study included 75 patients aged between 6 and 18 
years, diagnosed with asthma for at least 1 year and able 
to perform spirometry appropriately. These patients were 
referred by doctors from SUS outpatient services or from 
services linked to the Health Department of the state of 
Alagoas, which is a reference for the treatment and medical 
monitoring of children and adolescents with asthma. 
Patients were non-smokers, had no other associated dis-
ease (pulmonary, cardiac or neurological) that could interfere 
in the evaluations nor had had upper respiratory tract infec-
tion in the last 30 days and/or exacerbation of asthma in the 
last week. In addition to clinical data obtained on admission, 
patients were classified according to severity of asthma in: 
intermittent, mild persistent, moderate persistent and severe 
persistent(1). Then, patients and their parents were informed 
about the discontinuation of medications that could affect 
the test results: systemic corticosteroids (3 weeks), antihista-
mines and inhaled corticosteroids (48 hours), and theophyl-
line and/or β-2 adrenergic agents (24 hours). 
Patients underwent immediate hypersensitivity puncture 
skin tests to aeroallergens: Dermatophagoides pteronyssinus, 
D. farinae e Blomia tropicalis (FDA Allergenics®), taking the 
solution of histamine (1 mg/mL) as positive control and the 
excipient solution, as negative. We considered as a positive 
result the test that induced papular induration, whose di-
ameter was higher than or equal to 3 mm(11). Patients with 
at least one positive test were defined as atopic and those in 
which all results were negative, as non-atopic.
After acclimatization for 5 minutes in a special room at 
22º C, children performed the measurement of their pul-
monary function while seated, with nose clip and Easy One 
spirometer (pm) (Cradle Medical Technology®, model 2010, 
USA). All were previously trained for the proper execution 
of spirometry(12). The values obtained (FEV
1
, forced vital 
capacity – FVC – and the relation between FEV
1
/FVC) were 
compared with normal values (Polgar and Promadhat(12)) 
and expressed in a percentage of the predicted value, being 
considered reference for the other evaluations. 
In addition, vital signs were assessed: heart rate (HR) and 
respiratory rate (RR), axillary temperature (AT), blood pressure 
(BP) and pulmonary auscultation (PA). We measured O
2
 pe-
ripheral saturation (SPO
2 
–
 
portable pulse oximeter, JG Moriya 
MI003®). During the evaluation the patients remained seated.
Patients were, then, submitted to the BPT with HSS at 
4.5%, which is the most widely used because it combines 
high sensitivity, specificity, reproducibility and it is standard-
ized(5), with an ultrasonic nebulizer (Pulmossonic Star Luxo II, 
Soniclear®) with 10 mL volume, flow rate around 1.25 mL/
minute (steady), 80% aerosol and diameter less than 4 microns. 
During the BPT, children inhaled HSS at 4.5% for increasing 
periods (0.5; 1; 2; 4 and 8 minutes) at intervals of 2 minutes, 
totaling 15 minutes and 30 seconds, depending on a positive 
response or not. FEV
1 
was measured 1 minute after the end 
of each inhalation. Drops of FEV
1
 equal or higher than 20% 
in relation to the basal value authorized the interruption of 
BPT. Patients who did not have a drop after 15 minutes and 
30 seconds of inhalation were categorized as having negative 
bronchoprovocation(4,5).
At the end of BPT, a new evaluation was performed: vital 
signs, PA and SpO
2
. Patients also received inhalation with β-2 
agonist agent of short duration (salbutamol aerosol via metered 
dose inhaler – 400 mcg/dose) to relieve possible bronchospasm.
For statistical analysis, initially, we performed the comparison 
between the different degrees of severity of asthma. The absence 
of differences made the patients with intermittent and persistent 
mild asthma comprise the IM Group while those with persistent 
moderate or severe asthma composed the MS Group. The IM 
Group worked as a control group, once the Research Ethics 
Committee of Universidade de Ciências da Saúde de Alagoas 
(Uncisal) did not authorize the submission of non-asthmatic 
individuals to BPT with HSS at 4.5%. All variables were also 
analyzed considering atopic patients versus non-atopic ones. 
Sample homogeneity was verified by the Kolmogorov-
Smirnov test. The variables analyzed did not present normal 
distribution, and their values were described as median val-
ues. The Kruskal-Wallis non-paramedic test was employed 
for variables such as time and percentage of FEV
1 
decrease, 
according to severity of asthma and the presence of atopic 
status. For the analysis of vital signs changes, we used the 
Mann-Whitney non-paramedic test. We considered as sta-
tistical significance when p≤0.05.
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The study was approved by the Research Ethics of 
Universidade Federal de São Paulo (Unifesp), protocol 1039/08, 
and Universidade de Ciências da Saúde de Alagoas (Uncisal), 
protocol 817/2008. Patients and their guardians were informed 
about the research and signed an informed consent form.
Results 
Out of all asthmatic patients referred to be submitted 
to BPT with HSS at 4.5% (n=96), eight patients were not 
admitted for having basal value of FEV
1
 70% lower than 
the predicted value, other eight because they presented other 
associated diseases that could interfere with the evaluations 
and five because they could not perform acceptable and re-
producible spirometry. Thus, 75 children and adolescents 
with asthma were included in the study.
Such patients, after the immediate hypersensitivity skin 
test, composed two groups: atopic (n=60) and non atopic 
(n=15) to household dust mites (Table 1). At the beginning 
of the outbreak, the two groups were similar in relation 
to age and predicted basal values of FEV
1
 (Table 1). BPT 
with HSS was positive in 58 patients (77.3%), 9 (60.0%) 
non-atopic and 48 (80.0%), atopic. Although there was 
no difference between the percentage values of FEV
1
 at 
the end of the test, the time needed for the drop to occur 
was significantly higher in the non-atopic. The percentage 
of FEV
1
 reduction in relation to basal values was higher 
among the atopic, when compared to non-atopic patients 
(Figures 1 and 2). Considering individuals with negative 
test, the mean reduction of the FEV
1
 was 2.6% (variation 
of <1 to 5%) among the non-atopic and 10.7% (variation 
of <1 to 17%) among atopics. Among the atopic patients, 
four patients (30%) presented reduction higher than 15%.
The initial analysis, considering the severity of asthma as 
variable, did not show statistically significant differences be-
tween patients with intermittent and mild persistent asthma, 
what allowed us to group them (intermittent + mild – IM 
Group). The same occurred in relation to patients with moder-
ate persistent asthma and severe persistent asthma (moderate 
group + severe – MS). However, among the non-atopics, the 
Table 1 - Clinical and anthropometric characteristics of children (described as median, higher and lower limits)
Atopic Non-atopic p-value
Gender (M/F) 38/22 4/11
Age (years)€ 10 (6 to 15) 11 (6 to 15) 0.273
6 to 7 years
8 to 10 years
≥11 years
12
23
25
04
01
10
BMI 17.1 (13 to 26) 18(13 to 26) 0.904
Initial FEV1 (% predicted)* 80.9 (70 to 119) 81.1 (70 to 117) 0.900
After FEV1 (% predicted)* 59.7 (28 to 91) 68.1 (41 to 114) 0.196
Skin prick test positive for:
D. pteronyssinus (%) 53 (88.3) 0
D. farinae (%) 37 (61.6) 0
Blomia tropicalis (%) 56 (93.3) 0
Asthma Severity*  
BPT+vo (% BPT+vo)
n
Intermittent 15
11 (73.3)
8
4 (50.0)
Mild persistent 21
14 (66.6)
2
1 (50.0)
Moderate persistent 16
15 (93.7)
5
4 (80.0)
Severe persistent 8
8 (100.0)
0
(0)
FEV1: forced expiratory volume in fist second; D. Dermatophagoides; BPT+vo: positive bronchoprovocation test; %BPT+vo: percentage of posi-
tive bronchoprovocation in relation to the group; *according to IV Brazilian Guidelines on Asthma Management 2006(1), before starting treatment; 
n.: number of individuals per group
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comparison between patients with persistent moderate asthma 
and patients with persistent severe asthma was not possible, 
due to the fact that there were no patients with severe per-
sistent asthma in this group. Among atopic and non-atopic 
patients, there were no significant differences regarding pre-
dicted basal values for the pulmonary parameters assessed 
according to asthma severity. Among the atopics, we verified 
significantly lower values in the ratio FEV
1
/FVC and in the 
peak of expiratory flux (PEF) in the MS patients after BPT 
with HSS, a fact that was not observed among non-atopics. 
Regarding the FEV
1
, a significant reduction was observed 
among those with M asthma in the non-atopic group. In the 
atopic group, there was a reduction on the time needed for 
the 20% drop of FEV
1
 to occur and higher percentage of drop 
in predicted FEV
1
 among those with MS asthma after BPT, 
which was not observed among the non atopic.
The comparative analysis of the presence or absence of 
atopy among patients, divided according severity of asthma, 
showed significant changes only in Forced Expiratory Flow 
from 25 to 75% (FEF
25-75
) in the IM Group, before and after 
bronchoprovocation, and it was higher among non-atopics. 
Variation of FVC was lower than 5% after bronchoprovoca-
tion. Comparison between MS subgroups showed that the 
predicted value of FEV
1
 after bronchoprovocation was lower in 
the atopics, as was the time needed for the 20% drop in FEV
1
. 
The presence of asthma induced by exercise was not evaluated. 
Vital signs represented by RR, HR, systolic BP (SBP), 
diastolic BP (DBP), AT and SpO
2
, both before and after 
bronchoprovocation, were similar between groups. Among 
atopics, there was an increase in HR and a decrease in SpO
2
, 
after bronchoprovocation in the IM subgroup. In this group 
there were no changes in other vital signs after the exam. 
In the MS subgroup, only the SpO
2
 decreased. In the non-
atopic group, there were no differences in vital signs before 
and after bronchoprovocation between subgroups.
Discussion
The BPT with saline solution proved to be safe, since its 
interruption was not necessary in any patient because of the 
emergence of adverse effects, by request of the patients or 
because they felt bad or uncomfortable during the procedure. 
In this study, BPT with HSS at 4.5% documented the 
presence of BH in 77% of patients, similar data to those ob-
served by other researchers (between 48.9 and 80%)(4-6,12,13). 
However, when considering the distinction between atopic 
and non-atopic, this rate reaches 80%, corroborating with 
other studies (4,5). 
The presence of atopy is associated with increased BH, 
possibly because of inflammatory changes triggered by 
repeated exposure to the allergen. On the other hand, the 
resulting BH causes increased inflammation response and 
symptoms(1). In the present study, patients that were sensi-
tive to dust mites were considered atopic, because the lat-
ter are the main etiologic agents of respiratory allergies in 
tropical areas(14).
Figure 1 - Time needed (seconds) for 20% reduction in FEV1, 
in the group of children and adolescents with asthma, according 
to presence of atopy
Non-atopic Atopic
Kruskal-Wallis test: p<0.001
0
200
400
600
800
Figure 2 - Reduction in FEV1 (percentage) in children and 
adolescents with asthma, according to presence of atopy
Atopic
Kruskal-Wallis test: p<0.05
0,6
0,5
0,4
0,3
0,2
0,1
0,0
Non-atopic
402
Rev Paul Pediatr 2012;30(3):397-403.
Bronchoprovocation with hypertonic saline solution in asthmatic children
The frequency of positive BPT with HSS at 4.5% was 
higher in patients with moderate and severe asthma, who 
remained more symptomatic. A similar finding was observed 
by other authors, who reinforced the existence of a direct 
relation between the number of wheezing episodes and de 
degree of BH(15,16). 
The presence of gradient response to BPT, with HSS at 
4.5%, depending on the severity of asthma was also docu-
mented. Although the two groups of patients were initially 
similar to FEV
1
, when submitted to BPT with HSS at 4.5%, 
those atopic with persistent or severe asthma presented a 
faster and more marked drop in FEV
1
 than the group with in-
termittent or mild persistent asthma. In a way, these findings 
support the idea that individuals with more severe asthma 
have more pronounced BH. Other studies have observed the 
relation between severity and bronchial reactivity by differ-
ent methods. Cassol et al found more profound decline in 
FEV
1
 in individuals with severe asthma, followed by those 
with moderate and severe, with exercise induced methods(16). 
Avital et al performed BPT with methacholine in children 
with mild or moderate asthma and confirmed the need for 
lower doses of methacholine to determine the drop of at least 
20% in FEV
1
 values, among those with moderate asthma(17).
Another point to consider regarding the parameter used 
for the diagnosis of BPT as positive: 20% drop in baseline(5) 
FEV
1 
or 15% drop(4,6), which alters the sensibility to BPT. 
Because of this, we fixed the positivity rate for BPT with 
HSS at 4.5% in 20%.
The measurement of FVC may vary depending on bronchial 
obstruction, elastic recoil, and muscular effort; the PEF reflects 
the proximal airways caliber and is a dependent effort(12). Thus, 
reduction of these values could mean bronchial obstruction 
caused by the test, as it could also suffer interference from the 
fatigue caused by the various spirometric tests performed. The 
median of FVC was reduced, in the IM Group, in 8.6% for 
non-atopic and 15.8% for atopic, and, in the MS Group, the 
reduction was of 1.4% for non-atopic and 18.6% for atopic. 
There was also a reduction in PEF, in which the median for the 
IM Group was of 19.6 (non-atopic) and 22.6% (atopic), as well 
as for the MS Group, 23.5 (non atopic) and 31.8% (atopic).
The FEF
25-75 
is considered the most sensitive parameter for 
the detection of obstruction in the populations at risk, and 
represents the changes in the peripheral airways of medium 
and small caliber(12,18). The reduction of this parameter was 
marked, taking as reference studies that considered as posi-
tive response the decrease in FEV
1
 and/or in the FEF
25-75 
of 
at least 25%(19). In the present study, we observed a decrease 
in the median of the IM Group of 27.4% (non-atopics) and 
34.5% (atopics), as well as in MS, of 36.1% (non-atopics) 
and 44.0% (atopics). As the variation of FVC was lower than 
5% after bronchoprovocation, the alterations of FEF
25-75 
may 
have resulted from the inhalation.
Considering the other clinical variables analyzed, there 
were no significant changes, except for the increase in HR 
in the IM atopic group. Even with this change, patients 
remained within normal limits, without health risks. The 
SpO
2
 showed a slight decrease in the atopic group, but the 
reduction, although statistically significant, apparently had 
no clinical significance, which was reduced from 98 to 97%, 
and the decline was more pronounced among those charac-
terized as atopic. A study performed by Solé et al found no 
relationship between the decrease in SpO
2
 and provocative 
concentration, and found no relation between the decrease 
in SpO
2 
and the percentage of FEV
1 
variation in BPT(20)
. 
BPT with HSS at 4.5% proved to be safe, easy to perform 
and required little cooperation from participants. At the 
end, most patients complained about the unpleasant taste 
of the salt, the excessive production of saliva, the prolonged 
duration of the test, particularly among those in which there 
was no induction, besides fatigue for the repeated spirometry 
calculations, especially in younger individuals.
In the present study, it was verified that BPT with HSS 
at 4.5% determines the gradient of answer in children and 
adolescents with asthma, according to the severity of the 
disease. Severe forms are followed by greater and faster 
drops in FEV
1
. The frequency of positive BPTs was higher 
among atopic patients, as well as in those with more severe 
asthma. According to some authors(1,2), the documentation 
of the presence of BH has been essential for the diagnosis of 
asthma, especially in patients with atypical forms. Thus, a 
BPT with SSF at 4.5%, which is safe, easy to perform, and 
allows documenting gradient intensity of asthma, should be 
an important instrument to be incorporated in the follow-
up of patients with asthma, because it allows an objective 
assessment of the disease. 
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